High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model-Reference-Cited by-同舟云学术

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model

Published:2017-03 Issue:3 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lenhard Justin R.¹²³,Smith Nicholas M.¹²,Bulman Zackery P.¹²,Tao Xun⁴,Thamlikitkul Visanu⁵,Shin Beom S.⁶,Nation Roger L.⁷,Li Jian⁷,Bulitta Jürgen B.⁴,Tsuji Brian T.¹²

Affiliation:

1. Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, Buffalo, New York, USA

2. School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, New York, USA

3. California Northstate University College of Pharmacy, Elk Grove, California, USA

4. Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA

5. Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

6. Catholic University of Daegu, Hayang, South Korea

7. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

Abstract

ABSTRACT Acinetobacter baumannii is emerging with resistance to polymyxins. In 24-h time-kill experiments, high-dose ampicillin-sulbactam in combination with meropenem and polymyxin B achieved additivity or synergy against 10 8 CFU/ml of two clinical A. baumannii isolates resistant to all three drugs (maximum reductions, 1.6 and 3.1 logs). In a 14-day hollow-fiber infection model, high-dose ampicillin-sulbactam (8/4 g every 8 h, respectively) in combination with meropenem (2 g every 8 h) and polymyxin B (1.43 mg/kg of body weight every 12 h with loading dose) resulted in rapid (96 h) eradication of A. baumannii .

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01268-16

Reference21 articles.

1. Acinetobacter baumannii : Emergence of a Successful Pathogen

2. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

3. Agents of Last Resort